Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Long-term imatinib therapy promotes bone formation in CML patients
Author: Fitter, S.
Dewar, A.
Kostakis, P.
To, L.
Hughes, T.
Roberts, M.
Lynch, K.
Vernon-Roberts, B.
Zannettino, A.
Citation: Blood, 2008; 111(5):2538-2547
Publisher: Amer Soc Hematology
Issue Date: 2008
ISSN: 0006-4971
Statement of
Stephen Fitter, Andrea L Dewar, Panagiota Kostakis, L. Bik To, Timothy P Hughes, Marion M Roberts, Kevin Lynch, Barrie Vernon-Roberts, and Andrew CW Zannettino
Abstract: Imatinib inhibits tyrosine kinases important in osteoclast (c-Fms) and osteoblast (PDGF-R, c-Abl) function, suggesting that long term therapy may alter bone homeostasis. To investigate this question, we measured the trabecular bone volume (TBV) in iliac crest bone biopsies taken from CML patients at diagnosis and again following 2-4 years of imatinib therapy. Half the patients (8/17) showed a substantive increase in TBV (> 2 fold), following imatinib therapy, with the TBV in the post treatment biopsy typically surpassing the normal upper limit for the patient's age group. Imatinib treated patients exhibited reduced serum calcium and phosphate levels with hypophosphatemia evident in 53% (9/17) of patients. In vitro, imatinib suppressed osteoblast proliferation and stimulated osteogenic gene expression and mineralised matrix production by inhibiting PDGF receptor function. In PDGF stimulated cultures, imatinib dose dependently inhibited activation of Akt and Crk L. Using pharmacological inhibitors, inhibition of PI3-kinase/Akt activation promoted mineral formation, suggesting a possible molecular mechanism for the imatinib mediated increase in TBV in vivo. Further investigation is required to determine if the increase in TBV associated with imatinib therapy may represent a novel therapeutic avenue for the treatment of diseases that are characterised by generalised bone loss.
Keywords: Mesenchymal Stem Cells; Humans; Phosphates; Calcium; Benzamides; Piperazines; Pyrimidines; Platelet-Derived Growth Factor; Antineoplastic Agents; Organ Size; Cell Proliferation; Gene Expression Regulation, Leukemic; Calcification, Physiologic; Enzyme Activation; Osteogenesis; Time Factors; Adult; Aged; Middle Aged; Female; Male; Adipogenesis; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-akt; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Imatinib Mesylate
Description: Copyright © 2007 by American Society of Hematology
Provenance: Prepublished online Nov 27, 2007
RMID: 0020080313
DOI: 10.1182/blood-2007-07-104281
Appears in Collections:Pathology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.